Potent New Antiviral Compound Shows Similar Inhibition and Structural Interactions with Drug Resistant Mutants and Wild Type HIV-1 Protease
Citations Over TimeTop 10% of 2007 papers
Abstract
The potent new antiviral inhibitor GRL-98065 (1) of HIV-1 protease (PR) has been studied with PR variants containing the single mutations D30N, I50V, V82A, and I84V that provide resistance to the major clinical inhibitors. Compound 1 had inhibition constants of 17-fold, 8-fold, 3-fold, and 3-fold, respectively, for PR(D30N), PR(I50V), PR(V82A), and PR(I84V) relative to wild type PR. The chemically related darunavir had similar relative inhibition, except for PR(D30N), where inhibitor 1 was approximately 3-fold less potent. The high resolution (1.11-1.60 Angstrom) crystal structures of PR mutant complexes with inhibitor 1 showed small changes relative to the wild type enzyme. PR(D30N) and PR(V82A) showed compensating interactions with inhibitor 1 relative to those of PR, while reduced hydrophobic contacts were observed with PR(I50V) and PR(I84V). Importantly, inhibitor 1 complexes showed fewer changes relative to wild type enzyme than reported for darunavir complexes. Therefore, inhibitor 1 is a valuable addition to the antiviral inhibitors with high potency against resistant strains of HIV.
Related Papers
- → Decomposing the Energetic Impact of Drug Resistant Mutations in HIV-1 Protease on Binding DRV(2010)51 cited
- → Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir(2015)46 cited
- → Molecular alteration in drug susceptibility against subtype B and C-SA HIV-1 proteases: MD study(2019)22 cited
- → Darunavir: A New HIV-1 Protease Inhibitor for the Treatment of HIV Infection(2008)2 cited
- → Free Energy Calculation And Decomposition Of Hiv-1 Protease-Darunavir Binding By MM-PB/GBSA And Thermodynamic Integration Method(2009)